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Abstract
Background: Replication-competent adenoviruses (Ad) produced cytotoxic effects on infected tumors and have
been examined for the clinical applicability. A biomarkers to predict the cytotoxicity is valuable in a clinical setting.
Methods: We constructed type 5 Ad (Ad5) of which the expression of E1A gene was activated by a 5′ regulatory
sequences of survivin, midkine or cyclooxygenase-2, which were highly expressed in human tumors. We also
produced the same replication-competent Ad of which the fiber-knob region was replaced by that of Ad35
(AdF35). The cytotoxicity was examined by a colorimetric assay with human tumor cell lines, 4 kinds of pancreatic, 9
esophageal carcinoma and 5 mesothelioma. Ad infectivity and Ad-mediated gene expression were examined with
replication-incompetent Ad5 and AdF35 which expressed the green fluorescence protein gene. Expression of cellular
receptors for Ad5 and AdF35 was also examined with flow cytometry. A transcriptional activity of the regulatory
sequences was investigated with a luciferase assay in the tumor cells. We then investigated a possible correlation
between Ad-mediated cytotoxicity and the infectivity/gene expression, the transcriptional activity or the p53
genotype.
Results: We found that the cytotoxicity was greater with AdF35 than with Ad5 vectors, but was not correlated with
the Ad infectivity/gene expression irrespective of the fiber-knob region or the E1A-activating transcriptional activity.
In contrast, replication-competent Ad produced greater cytotoxicity in p53 mutated than in wild-type esophageal
carcinoma cells, suggesting a possible association between the cytotoxicity and the p53 genotype.
Conclusions: Sensitivity to Ad-mediated cytotoxic activity was linked with the p53 genotype but was not lineally
correlated with the infectivity/gene expression or the E1A expression.
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Background
A number of clinical trials for cancer therapy with
replication-competent viruses have been conducted and
some of the agents are approved in China, Unites States
and Europe [1, 2]. Adenoviruses (Ad) are one of the
agents extensively investigated and are easy to be genet-
ically manipulated to produce replication-restricted
types for human tumors. There are mainly 2 structural
categories that make preferential replications in tumors,
Ad defective of a region that inhibits viral replications in
non-tumorous cells such as the E1B 55 kDa-defective
type [3] and Ad of which the E1A region is activated
with a transcriptional regulatory unit of a gene which is
preferentially up-regulated in human tumors. Prediction
of Ad-mediated cytotoxicity is important for selecting
candidate patients who are suitable for the virotherapy
in a clinical setting but such a predictive biomarker for
the cytotoxicity remains uncharacterized.
Efficacy of the viral replication-mediated cell death
can be influenced by Ad infectivity and also by a
transcriptional activity of an exogenous promoter
region to activate the E1A region in the second type.
Nevertheless, few reports extensively analyzed correl-
ation between the Ad-mediated cytotoxicity and the
infectivity or the E1A-activating capacity. On the
other hand, further understanding of Ad biology
enabled us to produce modified Ad of which the
infectivity was changed by replacing the fiber-knob
region since the region mediated Ad binding to the
cellular receptors [4]. Ad use different receptor
molecules, depending on the subtypes. Consequently,
substituting the fiber-knob region can convert the
infectivity based on the Ad subtypes. Conventional
Ad vector belongs to type 5 (Ad5) and uses coxsachie
adenovirus receptor (CAR) as the main cellular
receptor and intergrin αvβ3 and αvβ5 as the axillar
receptor, whereas type 35 Ad (Ad35) vector uses
CD46 as the main receptor [5]. Ad5 bearing the
Ad35-derived fiber-knob structure (AdF35) therefore
infected CD46-positive cells irrespective of CAR
expression [6, 7]. The expression levels of CAR
molecules in human tumors were variable and often
down-regulated, rendering replication-competent Ad5
less cytotoxic to human tumors [8]. In contrast,
CD46 was ubiquitously expressed in human cells and
the expression was rather up-regulated in a number
of human tumors [9]. AdF35 can therefore infect hu-
man tumors better than Ad5 [10] and consequently
produced greater cytotoxicity [11].
Cytotoxic activities of the replication-competent Ad of
which the E1A is regulated by an exogenous regulatory
region can also be attributable to transcriptional
activities of the region in target cells. We and others
previously showed that a 5′ untranslated region of
midkine (MK) [12], survivin (Sur) [13] or cyclooxygen-
ase-2 (COX-2) gene [14], all of which were up-regulated
in the expression in a number of human tumors, acti-
vated a reporter gene in human tumors but much less in
human normal cells. Replication-competent Ad powered
by the promoter region in fact produced preferential
cytotoxicity in various type of human tumors with little
damages in non-transformed cells [15–17]. Replacement
of the fiber-knob region with the Ad35-derived one can
widen the target tumor scopes and furthermore produce
better cytotoxicity [18]. In a clinical setting, a possible
biomarker to predict the efficacy of these Ad is desirable
to narrow down candidate patients. We therefore tested
the cytotoxicity of replication-competent Ad5 and
AdF35 bearing the same transcriptional regulatory
region in 3 kinds of human tumors which include 4
pancreatic, 9 esophageal carcinoma and 5 mesothelioma
cell lines, and examined whether Ad infectivity and the
transactivation activity could be a predictive marker. We
also examined a possible linkage between the p53 geno-
type and the cytotoxicity with the esophageal carcinoma.
Methods
Cells
Human pancreatic carcinoma, PANC-1 (TKG 0606, p53
genotype: mutated), AsPC-1 (JCRB1454, null), MIA-
PaCa-2 (TKG 0227, mutated) and BxPC-3 (JCRB1448,
mutated) cells, and human esophageal carcinoma, TE-1
(TGK 0252, mutated at codon 272 Val to Met), TE-2
(TGK 0253, wild-type), TE-10 (TKG 0261, mutated at
codon 242 Cys to Tyr), TE-11 (TKG 0262, wild-type),
YES-2 (mutated at codon 236 Tyr to Asn) [19], YES-4
(wild-type) [20], YES-5 (mutated at codon 280 Arg to Gly)
[20], YES-6 (wild-type) [20] and T.Tn (JCRB 0261, mu-
tated at codon 214 His to Arg and 258 Glu to stop) cells
were from Cell Resource Center for Biomedical Research
(TKG number; Sendai, Japan), National Institutes of
Biomedical Innovation, Health and Nutrition (JCRB num-
ber; Tokyo, Japan) or Dr. Yutaka Shimada (YES-2, YES-4,
YES-5 and YES-6; Kyoto University, Kyoto, Japan).
HEK293 cells (CRL-1573) and human mesothelioma,
NCI-H2452 (CRL-5946, wild-type but truncated p53 pro-
tein), NCI-H2052 (CRL-5915, wild-type), NCI-H226
(CRL-5826, wild-type), NCI-H28 (CRL-5820, wild-type)
and MSTO-211H (CRL-2081, wild-type) cells, were from
ATCC (CRL number; Manassas, VA, USA). All the cells
were cultured with RPMI 1640 supplemented with 10%
fetal calf serum.
Construction of ad
Replication-incompetent Ad5 expressing the β green
fluorescence protein gene (GFP) (U55762) powered by
cytomegalovirus promoter (Ad5/GFP) were prepared
with Adeno-X expression system (Takara, Shiga, Japan),
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which included ligation of transgene-harboring pShuttle
2 and Adeno-X vectors followed by transfection into
HEK293 cells. AdF35, bearing the above transgene
(AdF35/GFP or AdF35/LacZ), were produced with the
Adeno-X vector of which the corresponding genomic
fragment (AY271307 at 30827–33609) was replaced with
that of the Ad35 DNA (Avior Therapeutic, Seattle, WA,
USA). These replication-incompetent Ad5 and AdF35
vectors used the same cytomegalovirus promoter
(BK000394) to activate the respective genes. Replication-
competent Ad5 or AdF35 in which the E1 gene was
activated by an exogenous regulatory element, Ad5/Sur,
Ad5/MK, Ad5/COX-2, AdF35/Sur, AdF35/MK and
AdF35/COX-2, were prepared by replacing the authentic
E1 promoter region with 5′ upstream regulatory
sequences of the MK (0.6 kb, D10604) [12] the Sur
(0.5 kb, U75285) [13], or COX-2 (0.3 kb, U04636) gene
[14]. Ad were purified with an Adeno-X virus
purification kit (BD Biosciences, San Jose, CA, USA) and
the numbers of virus particles (vp) per ml was estimated
with the formula, absorbance at 260 nm of purified Ad in
the presence of 0.1% sodium dodecyl sulfate × 1.1 × 1012.
Cytotoxicity of ad
Cells (5 × 103/well) were seeded in 96-well plates and
were cultured for 5 days with different amounts of
Ad (vp/cell). Cell viability was determined with a cell
proliferation colorimetric WST kit (Wako, Osaka,
Japan). The amount of formazan produced was
determined with the absorbance at 450 nm and the
relative viability was calculated based on the absorb-
ance without any treatments. Half maximal inhibitory
concentration (IC50) was estimated with CalcuSyn
software (Biosoft, Cambridge, UK).
Ad infectivity/ad-mediated gene expression
Cells were infected with Ad5/GFP or AdF35/GFP at 30
multiplicity of infection (MOI) for 30 min and were
washed to remove Ad. Infected cells were cultured for
2 days and then analyzed for percentages of GFP-posi-
tive cells with FACSCalibur (BD Biosciences) and Cell-
Quest software (BD Biosciences). Cells of which
fluorescence was greater than the brightest 5% of unin-
fected cells were judged as positively stained.
Expression of ad receptor molecules
Cells were stained with either anti-CAR antibody (Ab)
(#05–644, Upstate, Charlottesville, VA, USA) followed
by fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG Ab or with FITC-conjugated anti-human
CD46 Ab (#555949, BD Pharmingen, San Jose, CA,
USA). They were then analyzed for their fluorescence in-
tensity with FACSCalibur and CellQuest software. Mean
fluorescence intensity of the staining profiles was
expressed as an arbitrary FL1 unit after standardizing in-
tensity by the second antibody, FITC-conjugated or
isotype-matched control Ab as 10 in the unit.
Transcriptional activity
Genomic fragments of a 5′-transcriptional regulatory
region of the 0.6 kb MK [12], the 0.5 kb Sur [13], or
the 0.3 kb COX-2 [14] gene were cloned into pGL-2
basic vector (Promega, Madison, WI, USA) that
contained the firefly luciferase gene. Plasmid DNA
containing the respective genomic fragments,
pGL-control vector (Promega) harboring the SV40 T
antigen promoter-linked firefly luciferase gene, or
pGL-basic vector without any transcriptional regula-
tory regions (Promega), and a control vector, the
renilla luciferase gene fused with the herpes simplex
virus-thymidine kinase gene promoter (pRL-TK,
Promega), at a molar ratio of 10:1, was transfected
into tumors with a lipofectin reagent (Life Technologies,
Gaithersburg, MD, USA). Cell lysate on day 2 was assayed
for the luciferase activity with the dual luciferase reporter
assay (Promega). The firefly luciferase activity was stan-
dardized with the amounts of luminescence produced by
renilla luciferase and the relative activity was expressed as
a percentage of the SV40 T antigen promoter-mediated
activity.
Western blot analysis
Lysate of cells treated with Ad was subjected to
sodium dodecyl sulfate polyacrylamide gel electro-
phoresis. The protein was transferred to a nylon filter
and was hybridized with Ab against γ-H2A histone
family member X (γ-H2AX) (#613401, BioLegend, San
Diego, CA, USA), p53 (DO-10 MS-187-P, Thermo
Fisher Scientific, Fremont, CA, USA), p21 (#2947,
Cell Signaling, Danvers, MA, USA) or β-actin (#4970,
Cell Signaling) as a control. The membranes were
developed with the ECL system (GE Healthcare,
Buckinghamshire, UK).
Results
Cytotoxicity of replication-competent Ad5 and AdF35
We examined cytotoxic activity of the replication-
competent Ad5 and AdF35 on human pancreatic and
esophageal carcinoma, and mesothelioma with the WST
assay. We compared relative cytotoxicity between Ad5
and AdF35 which were activated by the same transcrip-
tional regulatory region and showed the cytotoxicity
with IC50 values which were expressed as vp per cell.
(Table 1, Additional file 1: Figure S1). The IC50 values of
AdF35 were in general lower than those of Ad5 irre-
spective of the regulatory regions. All the 4 pancreatic
carcinoma cells showed the sensitivity to replication-
competent AdF35 greater than Ad5 driven by MK, Sur
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and COX-2 regions. In contrast, some of esophageal car-
cinoma and mesothelioma cells did not produce such
sensitivity to AdF35 vectors. Ad5/MK-infected TE-10,
TE-11 and YES-4, and Ad5/Sur-infected YES-4 and
YES-6 cells in esophageal carcinoma, and Ad5/MK-in-
fected NCI-H2452, NCI-H226 and NCI-H28 cells, Ad5/
Sur-infected NCH-226 cells and Ad5/COX-2-infected
NCI-H2452 cells in mesothelioma, achieved greater
cytotoxicity than corresponding AdF35 vectors. The
cases that showed increased sensitive to Ad5 were how-
ever relatively limited, only 5 paired cases out of total 27
cases of esophageal carcinoma (9 cell kinds and 3 types
of the regulatory regions), and 5 cases out of 15 cases of
mesothelioma (5 cell kinds and 3 types). These data col-
lectively showed that AdF35 achieved greater cytotoxic
effects than prototype type 5 Ad and suggested that dif-
ferential infectivity by the fiber-knob replacement influ-
enced the cytotoxicity.
Correlation of ad infectivity and receptor
We used Ad5 and AdF35 vectors expressing the GFP gene
and tried to show the Ad infectivity with a percentage of
GFP-positive cells. The percentages did not directly reflect
the Ad infectivity since GFP fluorescence was influenced
by the other factors such as the promoter activity to acti-
vate the GFP gene and GFP protein stability in respective
cells. The GFP-positive percentages were therefore indir-
ect estimation of Ad infectivity. We compared the putative
infectivity, which included GFP expression ability,
between Ad5/GFP and AdF35/GFP in the same cells
(Table 2, Additional file 2 Figure S2). The infectivity was
greater with AdF35 than with Ad5 vectors in all the tumor
cells tested although the enhanced infectivity level by
replacing the fiber-knob region was variable among the
cells. Infectivity to HEK293 cells was much greater than
these tumor cells, and the transduction efficacy with Ad5
and AdF35 was similar at 30 MOI. We noticed that the
differential infectivity in NCI-H226 and NCI-H28 cells
was also small because these cells were susceptible to
Ad5-mediated infection. We then examined an expression
level of the major receptor molecules, CAR for Ad5 and
CD46 for AdF35 vectors, based on the expression in
HEK293 cells as a standard. The CAR expression level of
all the tumor cells was lower than that of HEK293 cells,
whereas the CD46 level in the tumor cells was greater
than that in HEK293 cells except MIA-PaCa-2 and
MSTO-211H cells. These data suggested that human
tumor cells tested in the present study expressed CD46
Table 1 Cytotoxicity of replication-competent Ad on carcinoma cells
Cells IC50 values (Average ± SE)
Ad5/MK AdF35/MK Ad5/Sur AdF35/Sur Ad5/COX-2 AdF35/COX-2
Pancreatic carcinoma (1 × 103 vp/cell)
AsPC-1 16.1 ± 2.7 9.2 ± 0.6 15.7 ± 0.5 3.6 ± 0.6 245 ± 41.5 38.8 ± 12.7
PANC-1 36.1 ± 8.8 13.7 ± 6.4 15.9 ± 2.6 2.6 ± 0.2 244 ± 77.1 27.6 ± 0.6
BxPC-3 44.6 ± 3.1 4.1 ± 2.0 64.9 ± 8.8 1.8 ± 0.9 474 ± 9.6 37.1 ± 7.1
MIA-PaCa-2 12.5 ± 2.7 2.2 ± 0.3 105 ± 16.3 8.0 ± 0.9 69.6 ± 5.4 32.1 ± 6.2
Esophageal carcinoma (1 × 104 vp/cell)
TE-1 32.2 ± 2.4 10.1 ± 2.0 56.0 ± 1.5 9.71 ± 4.7 317 ± 96.5 18.5 ± 1.9
TE-2 244 ± 188 28.6 ± 4.6 100 ± 32.6 15.1 ± 3.9 62.8 ± 19.9 46.6 ± 22.3
TE-10 2.6 ± 1.1 12.3 ± 4.7 27.3 ± 8.6 3.7 ± 0.6 46.1 ± 6.3 8.1 ± 1.6
TE-11 1.5 ± 0.3 3.0 ± 0.5 1.5 ± 0.3 1.1 ± 0.5 30.9 ± 11.8 7.7 ± 1.6
YES-2 5.7 ± 2.4 0.3 ± 0.2 7.6 ± 1.7 1.4 ± 0.6 80.1 ± 18.7 4.0 ± 2.7
YES-4 1.2 ± 0.8 10.6 ± 1.6 2.1 ± 0.3 7.1 ± 2.8 18.8 ± 4.7 5.6 ± 1.0
YES-5 16.7 ± 6.3 1.5 ± 1.0 8.1 ± 3.1 5.8 ± 1.9 37.5 ± 7.8 16.8 ± 5.3
YES-6 424 ± 85.2 157 ± 40.9 89.5 ± 21.5 226 ± 14.5 260 ± 43.1 40 ± 1.9
T.Tn 9.6 ± 0.9 1.0 ± 0.2 36.1 ± 1.2 1.1 ± 0.0 58.2 ± 19.0 6.0 ± 0.7
Mesothelioma (1 × 103 vp/cell)
NCI-H2452 7.18 ± 1.0 18.2 ± 6.2 43.1 ± 2.9 27.2 ± 9.0 41.6 ± 11.7 50.8 ± 5.8
NCI-H2052 520.6 ± 14.8 143.2 ± 24.8 516.1 ± 11.3 187.2 ± 50.9 >1000 524.0 ± 18.1
NCI-H226 35.1 ± 3.5 59.3 ± 0.6 55.5 ± 1.1 55.7 ± 2.5 550.0 ± 10.0 531.3 ± 11.3
NCI-H28 4.4 ± 0.4 5.6 ± 0.1 45.9 ± 21.1 7.1 ± 0.1 140.3 ± 23.7 36.6 ± 2.1
MSTO-211H 12.6 ± 2.2 0.7 ± 0.0 95.0 ± 19.1 3.9 ± 0.2 450.6 ± 17.2 10.9 ± 2.0
Respective carcinoma cells were infected with Ad at various vp/cell ratios and the cytotoxicity was tested with the WST assay. The experiments were conducted 3
times and the representative data are shown. IC50 values were estimated with CalcuSyn software. Averages and SEs are shown (n = 3)
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relatively well in comparison with CAR molecules and
consequently AdF35 infected greater than Ad5 in these
tumor cells.
We then investigated any possible correlation between
Ad infectivity/gene expression and the receptor
expression level (Table 3, Additional file 3: Figure S3 for
individual data). The correlation coefficient between
CAR levels and Ad5/GFP was −0.13 (P = 0.87) in pan-
creatic carcinoma, 0.62 (P = 0.07) in esophageal carcin-
oma and 0.68 (P = 0.21) in mesothelioma, indicating no
significant correlation in all the cells tested. The correl-
ation coefficient between CD46 and AdF35/GFP was
also not significant, −0.20 (P = 0.80) in pancreatic
carcinoma, 0.14 (P = 0.71) in esophageal carcinoma and
0.72 (P = 0.16) in mesothelioma. These data clearly
showed no linear correlation between the major receptor
expression level and the Ad infectivity/gene expression
in both Ad5 and AdF35 vectors.
Correlation of ad infectivity and ad-mediated cytotoxicity
We next investigated possible effects of Ad infectiv-
ity/gene expression on the cytotoxicity produced by
Ad with different transcriptional regulatory elements.
We used average IC50 values as the cytotoxicity by re-
spective replication-competent Ad and GFP-positive
percentages as the infectivity, and calculated correl-
ation coefficients among 4 pancreatic, 9 esophageal
and 5mesothelioma cells (Table 4, Additional file 4:
Figure S4 for individual data). Analyses with pancre-
atic carcinoma cells showed positive correlation
except AdF35/MK-mediated cytotoxicity but none of
them were statistically significant, and those with all
the esophageal carcinoma had negative correlation
without statistical significance. A half of mesothelioma
cases was positively and the other was negatively
correlated, and none of them was statistical signifi-
cant. These data clearly indicated no significant linear
Table 2 Infectivity/gene expression of Ad5/GFP and AdF35/GFP, and expression levels of CAR and CD46 on target cells
Infectivity tested at MOI = 30 Receptor expression
Cells Ad5/GFP AdF35/GFP CAR CD46
(% positive cellsa) (% mean fluorescence intensityb)
Pancreatic carcinoma
HEK293 98.98 ± 0.11 99.47 ± 0.11 100 100
AsPC-1 8.47 ± 0.27 25.32 ± 0.57 71.6 182.4
PANC-1 7.66 ± 0.50 28.35 ± 0.41 65.5 175.7
BxPC-3 19.48 ± 0.62 68.95 ± 0.45 26.8 231.1
MIA-PaCa-2 5.89 ± 0.54 65.41 ± 0.68 2.0 62.6
Esophageal carcinoma
HEK293 87.20±0.52 78.05±0.70 100 100
TE-1 8.06±1.17 53.47±0.10 11.5 321.5
TE-2 0.79±0.14 10.15±0.44 33.7 160.2
TE-10 16.15±0.52 35.33±0.67 25.9 99.7
TE-11 22.86±0.53 42.82±0.74 39.1 290.2
YES-2 5.09±1.29 51.54±0.36 0.3 131.7
YES-4 27.18±0.16 61.23±0.07 47.2 135.2
YES-5 22.18±0.32 69.97±0.89 27.0 176.3
YES-6 16.59±0.25 27.63±0.17 53.1 120.4
T.Tn 0.49±1.00 21.60±0.15 14.3 208.9
Mesothelioma
HEK293 93.7±0.1 93.8±0.4 100 100
NCI-H2452 49.8±0.3 75.3±0.6 35.6 117.6
NCI-H2052 7.4±0.3 81.5±0.5 0.7 174.7
NCI-H226 78.5±1.2 81.9±1.5 84.0 164.7
NCI-H28 85.5±0.4 95.1±0.2 17.8 150.4
MSTO-211H 8.7±0.3 67.9±0.9 2.3 56.0
Cells infected with Ad5/GFP or AdF35/GFP at 30 MOI were analyzed for the fluorescence intensity with flow cytometry. aPositively stained cells were defined as
those that showed fluorescence greater than the brightest 5% of uninfected cells. Averages and the SEs are shown (n = 3). bCAR and CD46 expression levels were
determined with flow cytometry and are expressed with arbitrary unit. The intensity is expressed as a percentage of that of HEK293 cells. Three tumor types were
respectively examined with HEK293 cells as a control
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correlation between the cytotoxicity and the Ad in-
fectivity/gene expression.
Correlation of transcriptional activity for E1 activation
and ad-mediated cytotoxicity
We further examined a transcriptional activity of the
regulatory regions which were used for activation of E1 re-
gion genes in target tumor cells (Table 5, Additional file 5:
Figure S5). We tested a luciferase activity powered by the
same promoter region in respective cells. The activity did
not precisely reflect the E1-activating ability in replicating
Ad since Ad proteins produced during the viral replica-
tions influenced the ability. We therefore used the lucifer-
ase activity as a putative E1 transcription marker in the
present study. The transcriptional activity was expressed
as a percentage of that of SV40 T antigen and the relative
activity showed that MK- and COX-2-mediated activities
were greater than SV40 T antigen-mediated activity irre-
spective of cell types. In contrast, Sur-mediated activities
were much variable depending on cells tested.
Table 4 Correlation between Ad-mediated cytotoxicity and Ad
infectivity/gene expression
Tumor type Infectivityb Correlation
coefficient
P value
Ad-mediated
cytotoxicitya
Pancreatic carcinoma
Ad5/MK Ad5/GFP 0.77 0.22
Ad5/Sur Ad5/GFP 0.05 0.95
Ad5/COX-2 Ad5/GFP 0.94 0.06
AdF35/MK AdF35/GFP −0.89 0.11
AdF35/Sur AdF35/GFP 0.31 0.69
AdF35/COX-2 AdF35/GFP 0.14 0.86
Esophageal carcinoma
Ad5/MK Ad5/GFP −0.15 0.70
Ad5/Sur Ad5/GFP −0.52 0.15
Ad5/COX-2 Ad5/GFP −0.22 0.56
AdF35/MK AdF35/GFP −0.36 0.34
AdF35/Sur AdF35/GFP −0.28 0.47
AdF35/COX-2 AdF35/GFP −0.53 0.13
Mesothelioma
Ad5/MK Ad5/GFP −0.57 0.31
Ad5/Sur Ad5/GFP −0.65 0.24
Ad5/COX-2 Ad5/GFP −0.18 0.82
AdF35/MK AdF35/GFP 0.10 0.87
AdF35/Sur AdF35/GFP 0.07 0.91
AdF35/COX-2 AdF35/GFP 0.15 0.82
aCytotoxicity data are expressed as IC50 values of respective cells, 4 pancreatic,
9 esophageal carcinoma and 5 mesothelioma cells as shown in Table 1
bInfectivity data are percentages of GFP-positive cells infected at Ad5/GFP or
AdF35/GFP at 30 MOI as shown in Table 2
Table 5 Transcriptional activity of the regulatory region in
target cells
Transcriptional activity (% activity of SV40 T antigen)
Cells MK Sur COX-2
Pancreatic carcinoma
AsPC-1 345 ± 59.9 75.6 ± 2.9 212 ± 11.5
PANC-1 224 ± 3.6 69.8 ± 4.28 243 ± 11.4
BxPC-3 454 ± 49.1 67.8 ± 10.6 363 ± 86.5
MIA-PaCa-2 182 ± 22.4 135 ± 7.0 783 ± 27.6
Esophageal carcinoma
TE-1 400 ± 99.0 162 ± 13.6 752 ± 71.9
TE-2 375 ± 7.9 610 ± 136.5 625 ± 28.1
TE-10 339 ± 26.9 906 ± 34.9 431 ± 59.5
TE-11 702 ± 30.2 6770 ± 526.0 410 ± 128.0
YES-2 314 ± 20.2 1790 ± 156.0 351 ± 27.1
YES-4 187 ± 2.6 310 ± 13.2 282 ± 18.5
YES-5 745 ± 47.7 395 ± 11.2 160 ± 12.5
YES-6 540 ± 7.4 3110 ± 96.8 417 ± 31.4
T.Tn 199 ± 32.0 2410 ± 233.0 126 ± 10.2
Mesothelioma
NCI-H2452 153 ± 45.7 35.0 ± 5.0 291 ± 72.4
NCI-H2052 189 ± 4.5 38.6 ± 1.0 233 ± 10.1
NCI-H226 112 ± 4.2 7.2 ± 0.3 381 ± 61.2
NCI-H28 348 ± 68.2 173 ± 62.1 250 ± 38.2
MSTO-211H 168 ± 18.4 134 ± 7.3 141 ± 14.0
Cells were transfected with plasmid vector DNA containing a regulatory region
linked with the luciferase gene and the transcriptional activity was expressed
as a percent luciferase activity of the SV40 T antigen. Three histological types
were respectively examined with SV40 T antigen as a control. Averages and
SEs are shown (n = 3)
Table 3 Correlation between Ad infectivity/gene expression
and receptor expression
Tumor
type
Infectivity Receptor expression Correlation P value
(% positive
cells)
(% mean fluorescence
intensity)
coefficient
Pancreatic carcinoma
Ad5/GFP CAR −0.13 0.87
AdF35/GFP CD46 −0.20 0.80
Esophageal carcinoma
Ad5/GFP CAR 0.62 0.07
AdF35/GFP CD46 0.14 0.71
Mesothelioma
Ad5/GFP CAR 0.68 0.21
AdF35/GFP CD46 0.72 0.16
Infectivity data and receptor expression levels of respective tumor types
(pancreas; 4 cells, esophagus; 9 cells, mesothelioma; 5 cells) are derived
from Table 2
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We then investigated correlation between the cytotox-
icity and the E1-activating ability (Table 6, Additional file 6:
Figure S6 for individual data). We used average IC50
values as the Ad-mediated cytotoxicity and an average lu-
ciferase activity as a putative transcriptional activity. Ana-
lyses of pancreatic carcinoma showed that correlation
coefficient was variable and only one case, cytotoxicity
with AdF35/Sur and the Sur-mediated luciferase activity,
was statistically correlated. Esophageal carcinoma and
mesothelioma cells showed also variability between the
cytotoxicity and the transcriptional activity, and none of
them was statistically correlated. These data collectively
demonstrated that the cytotoxicity was in general inde-
pendent of the transcriptional activity of the regulatory
regions.
Correlation of p53 genotype and ad-mediated cytotoxicity
We therefore examined a possible linkage between
the p53 genotype and the cytotoxicity. The p53
genotype of all the pancreatic carcinoma was either
mutated (PANC-1, BxPC-3 and MIA-PaCa-2) or de-
leted (AsPC-1), and that of all the mesothelioma was
wild-type except NCI-H2452 cells which had
truncated p53 protein despite the wild-type p53 gene.
The distribution of the p53 genotypes in pancreatic
carcinoma and mesothelioma was not even, which
made it difficult to analyze the linkage in the same
tumor type. We then investigated cytotoxicity of
esophageal carcinoma, which included 5 cells with
mutated (TE-1, TE-10, YES-2, YES-5 and T.Tn) and 4
cells with wild-type p53 gene (TE-2, TE-11, YES-4
and YES-6). We examined IC50 values produced by
all the replication-competent Ad irrespective of the regu-
latory regions with regard to the p53 genotype. The IC50
values tested with p53-wild-type cells (average ± SE:
74.4 ± 22.5 × 104 vp/cell) (n = 24; 4 cells × 2 vectors with
different fiber-knob region × 3 regulatory regions) were
greater than those of p53-mutated cells (28.0 ± 10.6,
n = 30) (P = 0.05) (Fig. 1). AdF35 vectors showed more
statistical difference (P = 0.04) with greater IC50 values in
the wild-type (45.7 ± 20.6, n = 12) than in mutant p53
gene (6.7 ± 1.5, n = 15). In contrast, Ad5 vectors did not
show the statistical difference (P = 0.21) with those in the
wild-type (103.0 ± 39.2, n = 12) and in mutant p53 gene
(49.4 ± 20.0, n = 15), but Ad5 tended to be more effective
to p53-mutant than the wild-type cells.
We further investigated whether p21 might play a role
in the cytotoxicity since previous studies showed contro-
versial data regarding the correlation [21, 22]. We
treated cells with cisplatin, a DNA damaging agent, and
examined a change of p21 expression (Fig. 2). Cisplatin
Table 6 Correlation between Ad-mediated cytotoxicity and the
transcriptional activity used in E1 activation
Tumor type Transcriptional Correlation
coefficient
P value
Ad-mediated
cytotoxicitya
activityb
Pancreatic carcinoma
Ad5/MK MK 0.57 0.43
Ad5/Sur Sur 0.80 0.20
Ad5/COX-2 COX-2 −0.58 0.42
AdF35/MK MK −0.16 0.84
AdF35/Sur Sur 0.99 0.01c
AdF35/COX-2 COX-2 −0.18 0.81
Esophageal carcinoma
Ad5/MK MK 0.17 0.67
Ad5/Sur Sur −0.18 0.65
Ad5/COX-2 COX-2 0.60 0.09
AdF35/MK MK 0.18 0.65
AdF35/Sur Sur 0.19 0.62
AdF35/COX-2 COX-2 0.48 0.19
Mesothelioma
Ad5/MK MK −0.07 0.92
AdF35/Sur Sur −0.27 0.66
Ad5/COX-2 COX-2 0.08 0.92
AdF35/MK MK −0.25 0.68
Ad5/Sur Sur −0.53 0.36
AdF35/COX-2 COX-2 0.54 0.35
aCytotoxicity data are expressed as IC50 values of respective cells, 4 pancreatic,
9 esophageal and 5 mesothelioma cell lines as shown in Table 1
bTranscriptional activity data are percentages of the SV40 T antigen promoter-
mediated luciferase activity as shown in Table 5
cStatistically significant
Fig. 1 Cytotoxicity of esophageal carcinoma to replication-competent
Ad in terms of the p53 genotypes and p21 responses to cisplatin
treatments. Ad-mediated cytotoxicity was expressed as IC50 values, which
was tested with Ad5/MK, AdF35/MK, Ad5/Sur, AdF35/Sur, Ad5/COX-2 and
AdF35/COX-2. A response of p21 levels to cisplatin was judged from
Western blot analysis in Fig. 2. Non-decreased cells were YES-2, YES-4 and
YES-6, and decreased cells were TE-1, TE-10, TE-11, YES-5 and T.Tn cells
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induced DNA damages, which was evidenced by in-
creased γ-HX2A expression. Cells with wild-type p53
gene in general increase the p53 expression but only
TE-11 and YES-4 cells augmented the expression
(Additional file 7 Figure S7). Cells with mutated p53
gene showed various responses, decreased in TE-1,
increased in YES-2 and T.Tn, and unchanged p53 in
TE-10 cells. The differential p53 responses were prob-
ably attributable to varied ubiquitination levels of p53 or
distinct p53 upstream pathways which mediate p53
phosphorylation in respective cells. A change of p21
expression was different from that of p53 although p21
is one of the p53 targets. The p21 levels decreased in
TE-1, TE-10, TE-11, YES-5 and T.Tn cells, but increased
in YES-2, even if temporally in YES-4 (Additional file 7
Figure S7). YES-6 cells remained unchanged and TE-2
cells were undetectable for p21. We tentatively classified
the cells into a p21-decreased group or non-decreased
group (YES-2, YES-4 and YES-6), and examined any
correlation between the p21 expression change and the
cytotoxicity. The IC50 values in the p21-decreased group
(26.3 ± 10.5, n = 30) were marginally different those in
the p21 non-decreased group (74.5 ± 28.0, n = 18)
(P = 0.06) (Fig. 1). AdF35 vectors showed statistical
difference (P = 0.05) with greater IC50 values in the non-
decreased group (50.2 ± 27.6, n = 9) than in the
decreased group (7.1 ± 1.4, n = 15). In contrast, Ad5
vectors did not show the statistical difference (P = 0.26)
with those in the non-decreased group (98.8 ± 49.2,
n = 9) and in the decreased group (45.4 ± 25.4, n = 15).
These data collectively suggested that cells with wild-
type p53 genotype were more resistant to replication-
competent Ad than those with mutated p53 genotype,
and cells with decreased p21 levels responding to DNA
damages were more sensitive than non-decreased cells
to the cytotoxicity.
Discussion
We investigated in the present study a possible correlation
between cytotoxicity produced by replication-competent
Ad and the infectivity/gene expression or a transcriptional
activity of an exogenous regulatory region that was used
to activate E1 region genes. We produced AdF35 which
differed only in the fiber-knob region and compared with
the prototype Ad5 in the cytotoxicity and the infectivity.
The present study demonstrated that replication-
competent AdF35 produced greater cytotoxicity than the
prototype Ad5 bearing the same regulatory region, but the
cytotoxicity irrespective of the Ad types was not correlated
with the infectivity/gene expression or transcriptional
activity of the region used for activation of E1 genes.
Nevertheless, we demonstrated that the p53 genotype
differentiated the sensitivity of esophageal carcinoma to
the Ad-mediated cytotoxicity with greater cytotoxicity in
p53-mutated cells than in p53 wild-type cells.
A biomarker to predict an oncolytic ability of replication-
competent Ad is important in the clinical applications. The
biomarker is useful to select a patient who responds to the
Ad-mediate cancer therapy and to exclude a patient who
suffers from severe adverse effects caused by the gene
Fig. 2 Western blot analysis of esophageal carcinoma treated with cisplatin. Cells were treated with 20 μM cisplatin for 24 or 48 h and the lysate
was subjected to gel electrophoresis. Expression of molecules was probed with respective Ab and actin was used as a loading control
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medicine. Improved cytotoxicity of AdF35 in comparison
with the corresponding Ad5 could be attributable to the
enhanced infectivity. Expression of CAR molecules, the
major cellular receptor of Ad5, was often down-regulated
in human tumors and in fact the present study showed that
the CAR expression levels in 3 kinds of human tumors
were lower than that of HEK293 cells. In contrast, the level
of CD46 molecules, the major receptor for Ad35, did not
decrease in the tumors and was rather higher than that in
HEK293 cells. The fiber-knob region of Ad5 and Ad35 is
responsible for binding with CAR and CD46 molecules,
respectively, and replacement of the Ad5-derived region
with the Ad35 region ablated the CAR binding ability and
enabled AdF35 bind to CD46 molecules. Nevertheless,
cytotoxicity of replication-competent Ad5 or AdF35 was
not directly correlated with infectivity/gene expression of
Ad5 or AdF35 vector irrespective of the transcriptional
regions used. These data suggest that expression of subsid-
iary Ad receptors such as integrin αvβ3 and αvβ5 can also
be pivotal for Ad infectivity/gene expression. The present
study demonstrated that GFP-positive percentages
produced by Ad5 or AdF35 vector were unrelated with
CAR and CD46 levels, respectively. Ad-mediated gene
expression is regulated at various steps and the infection
process can also be influenced by a threshold of the recep-
tor expression. The GFP expression was thereby not
directly or linearly associated with the major receptor
expression levels. Contribution of the major receptors to
the infectivity can be limited in particular in cells with
CAR-low or CD46-low expression. Lyle et al. in fact
demonstrated that integrin αvβ5 worked as the primary
receptor in CAR-negative cells [23]. Previous studies also
suggested that infectivity of Ad5 or Ad5 bearing type
11-derived fiber-knob region, which used CD46 molecules
as the major receptor, was not directly correlated with the
cytotoxicity although the studies did not analyzed statisti-
cally [24]. Increased CAR expression augmented Ad5
infectivity and the Ad5-mediated cytotoxicity [25, 26], but
correlation between the CAR expression and Ad5 infectiv-
ity was not extensively investigated. In contrast, the
present study statistically demonstrated that increased Ad
infectivity/gene expression was not associated with the Ad
replication-mediated cytotoxicity.
We also analyzed the E1-activating ability of Ad in the
infected cells since E1A protein or the transcript levels
were linked with the cytotoxic activity of the Ad [24, 27].
The present study showed that the transcriptional activity
of respective regulatory regions varied depending on
target cells and the region integrated in Ad. The activities
of MK and COX-2 were constantly greater than that of
SV40 T antigen, whereas the Sur activity was variable in
comparison with that of SV40 T antigen. The variability of
Sur activities in the tumors tested could be partly attribut-
able to preferential expression of the Sur gene at G2/M
phase [28]. Nevertheless, the present study demonstrated
that the E1A-activation ability was not directly correlated
with the cytotoxicity except one case, AdF35/Sur-medi-
ated cytotoxicity and Sur activity in pancreatic carcinoma.
The previous studies which analyzed a possible linkage
between E1A expression and the cytotoxicity did not
analyze statistical significance [24, 27], but the present
study was to our knowledge the first report to demon-
strate no significant association between them. These data
consequently suggest that a cellular factor play an import-
ant role in the Ad-mediated cytotoxicity. A mechanism of
Ad replication-induced cell death is complex and the cell
death pathways might be different among the cells tested.
We examined a correlation between the p53 genotype
and the cytotoxic activity with esophageal carcinoma
and demonstrated that cells with wild-type p53 gene
were resistant to Ad replication-induced cytotoxicity
compared with those with mutant p53 in particular with
the AdF35 vectors. Previous studies showed that trans-
duction with the wild-type p53 enhanced cytotoxicity
produced by replication-competent Ad [29, 30] and that
the Ad-mediated cytotoxicity, which was further aug-
mented by co-expressed p53, was independent of the
p53 status of target cells [30, 31]. Expression of E1A ac-
companied by the viral replications enhanced expression
of p53 and the phosphorylation, which contributed to
augmentation of cell death. In contrast, the E1A-
induced phosphorylation of mutated p53, functioned as
a dominant-negative form, increased the resistance to
cell death, which consequently augmented viral replica-
tions and production of viral progenies. The differential
susceptibility of replication-competent Ad in terms of
the p53 genotype can be attributable to how infected
cells were subjected to death and to how much viral pro-
genies were produced through preventing premature cell
death. A number of factors were involved in a balance
between survival and death signals, such as differential
activities between apoptotic and anti-apoptotic path-
ways, and autophagy and anti-autophagy pathways, as
well as cellular components that influence viral progeny
production. Further investigations, for example, a treat-
ment with siRNA for p53, are required to clarify a pos-
sible role of p53 in the Ad-mediated cytotoxicity.
Functional significance of p21, one of the p53 down-
stream molecules, in the Ad-mediated cytotoxicity was
controversial. Flak et al. showed that cells with inducible
p21 were susceptible to replication-competent Ad [21],
whereas Höri et al. demonstrated that a chemical agent
to augment p21 expression decreased the cytotoxicity
[22]. We treated cells with cisplatin, a representative
agent to induce DNA damages, and examined p21
expression. Cells infected with replication-competent Ad
were not used since they were difficult to be standard-
ized for the DNA damages during viral replications.
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Increased p21 expression can inhibit cell cycle progres-
sion at G1 phase and consequently decreases viral repli-
cations. On the other hand, p21 is inhibitory to cell
death, which makes cells alive and productive of viral
particles. A functional role of p21 in viral replications
and the cytotoxicity is thus divalent and can be differen-
tially influenced by properties of the infected cells. The
current study showed that decreased p21 expression
after DNA damages was associated with increased sus-
ceptibility to Ad-mediated cytotoxicity and indicated
that down-regulation of p21 facilitated cell cycle pro-
gression to make cells competent for viral replications
and favored cell death. Biological significance of the
down-regulated p21 in terms of the cytotoxicity needs
further studies since Ad-mediated cytotoxicity is influ-
enced not only by viral replications but susceptibility to
cell death mechanisms. We noticed that the mutated
p53 esophageal carcinoma tended to decreased p21
expression, and consequently mutated p53 genotype and
decreased p21 levels could be relevant to each other
regarding the Ad-mediated cytotoxicity. In addition,
responses of p53 and p21 to cisplatin in esophageal car-
cinoma were different from typical damage responses,
which suggested that the p53 pathways were impaired.
We however found that cisplatin-treated cells induced
cleavage of PARP and caspase-3 in all the p53 wild-type
esophageal carcinoma (Additional file 8: Figure S8), indi-
cating that apoptosis was induced by cisplatin. We also
showed that association of the cytotoxicity with the p53
genotype or with the p21 responses was greater with
AdF35 than with Ad5 vectors, but the mechanism
behind this vector difference was currently unknown.
The present study suggested the p53 genotype as a po-
tential biomarker to predict the efficacy but this out-
come needs to be confirmed with clinical specimens.
Moreover, expression of cellular proteins necessary for
Ad replications such as nuclear factor-1 and production
of type I interferon followed by Ad infection are also
issues to be examined since these factors also influence
susceptibility of target cells to Ad-mediated cell death
[32–34]. Prediction of Ad-mediated cytotoxicity is
important from the standpoint of the possible clinical
application, and further investigations are required to
establish such predictive markers because genetic and
epigenetic alterations in target cells are involved in the
Ad-mediated cytotoxicity.
Conclusions
We examined biomarkers that could influence Ad-
mediated cytotoxicity. We initially presumed that Ad
infectivity/gene expression and transcriptional activity of
the regulatory regions played a certain role in the cyto-
toxicity, but the present analyses showed that these
factors were scarcely correlated with the cytotoxicity.
We however demonstrated that the cytotoxicity was
greater in p53 mutated than in wild-type esophageal
carcinoma cells and perhaps was associated decreased
p21 levels.
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probed with the antibody as indicated, poly (ADP-ribose) polymerase
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also detect caspase-3, #9661) (Cell Signaling). Actin was used as a loading
control and the blot was the same as that in Fig. 2. Data of untreated YES-6
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